Systematic review with meta-analysis: The incidence of advanced neoplasia after polypectomy in patients with and without low-risk adenomas

C. Hassan, A. Gimeno-García, M. Kalager, C. Spada, A. Zullo, G. Costamagna, C. Senore, Douglas Rex, E. Quintero

Research output: Contribution to journalArticle

29 Citations (Scopus)

Abstract

Background Patients with one to two tubular adenomas <1 cm in size without high-grade dysplasia (low-risk group) are considered at low risk for colorectal cancer. However, it is uncertain whether they have the same risk of subsequent advanced neoplasia as those with no neoplasia at baseline colonoscopy. Aim To compare incidence of metachronous advanced neoplasia between patients in the low-risk adenoma group and those without neoplasia at index colonoscopy. Methods Relevant publications were identified by MEDLINE/EMBASE and other databases for the period 1992-2013. Studies comparing the incidence of post-polypectomy advanced neoplasia (adenomas ≥10 mm/high-grade dysplasia/villous or cancer) between the low-risk group and patients without colorectal neoplasia at the first colonoscopy were included. Detection rates for advanced neoplasia at endoscopic surveillance were extracted. Study quality was ascertained according to Newcastle-Ottawa Scale. Forest plot was produced based on random-effect models. Inter-study heterogeneity was assessed using the I2 statistic. Results Seven studies provided data on 11 387 patients. Mean surveillance periods ranged between 2 and 5 years. Altogether, 267 patients with post-polypectomy advanced neoplasia were detected in the two groups. The incidence of advanced neoplasia was 1.6% (119/7308) in those without neoplasia and 3.6% (148/4079) in those with low-risk adenoma, respectively, corresponding to a relative risk of 1.8 (95% CI: 1.3-2.6). Inter-study heterogeneity was only moderate (I2: 37%). No publication bias was present. Conclusions Patients with low-risk adenomas at baseline had a higher risk of metachronous advanced neoplasia than the group with no adenomas at baseline, though the absolute risk was low in both groups.

Original languageEnglish (US)
Pages (from-to)905-912
Number of pages8
JournalAlimentary Pharmacology and Therapeutics
Volume39
Issue number9
DOIs
StatePublished - May 2014

Fingerprint

Adenoma
Meta-Analysis
Incidence
Neoplasms
Colonoscopy
Publication Bias
MEDLINE
Publications
Colorectal Neoplasms
Cohort Studies
Databases

ASJC Scopus subject areas

  • Hepatology
  • Gastroenterology
  • Pharmacology (medical)

Cite this

Systematic review with meta-analysis : The incidence of advanced neoplasia after polypectomy in patients with and without low-risk adenomas. / Hassan, C.; Gimeno-García, A.; Kalager, M.; Spada, C.; Zullo, A.; Costamagna, G.; Senore, C.; Rex, D. K.; Quintero, E.

In: Alimentary Pharmacology and Therapeutics, Vol. 39, No. 9, 05.2014, p. 905-912.

Research output: Contribution to journalReview article

Hassan, C, Gimeno-García, A, Kalager, M, Spada, C, Zullo, A, Costamagna, G, Senore, C, Rex, DK & Quintero, E 2014, 'Systematic review with meta-analysis: The incidence of advanced neoplasia after polypectomy in patients with and without low-risk adenomas', Alimentary Pharmacology and Therapeutics, vol. 39, no. 9, pp. 905-912. https://doi.org/10.1111/apt.12682
Hassan, C. ; Gimeno-García, A. ; Kalager, M. ; Spada, C. ; Zullo, A. ; Costamagna, G. ; Senore, C. ; Rex, D. K. ; Quintero, E. / Systematic review with meta-analysis : The incidence of advanced neoplasia after polypectomy in patients with and without low-risk adenomas. In: Alimentary Pharmacology and Therapeutics. 2014 ; Vol. 39, No. 9. pp. 905-912.
@article{b2f481632f5744c0ac63f7ba0bc47a4c,
title = "Systematic review with meta-analysis: The incidence of advanced neoplasia after polypectomy in patients with and without low-risk adenomas",
abstract = "Background Patients with one to two tubular adenomas <1 cm in size without high-grade dysplasia (low-risk group) are considered at low risk for colorectal cancer. However, it is uncertain whether they have the same risk of subsequent advanced neoplasia as those with no neoplasia at baseline colonoscopy. Aim To compare incidence of metachronous advanced neoplasia between patients in the low-risk adenoma group and those without neoplasia at index colonoscopy. Methods Relevant publications were identified by MEDLINE/EMBASE and other databases for the period 1992-2013. Studies comparing the incidence of post-polypectomy advanced neoplasia (adenomas ≥10 mm/high-grade dysplasia/villous or cancer) between the low-risk group and patients without colorectal neoplasia at the first colonoscopy were included. Detection rates for advanced neoplasia at endoscopic surveillance were extracted. Study quality was ascertained according to Newcastle-Ottawa Scale. Forest plot was produced based on random-effect models. Inter-study heterogeneity was assessed using the I2 statistic. Results Seven studies provided data on 11 387 patients. Mean surveillance periods ranged between 2 and 5 years. Altogether, 267 patients with post-polypectomy advanced neoplasia were detected in the two groups. The incidence of advanced neoplasia was 1.6{\%} (119/7308) in those without neoplasia and 3.6{\%} (148/4079) in those with low-risk adenoma, respectively, corresponding to a relative risk of 1.8 (95{\%} CI: 1.3-2.6). Inter-study heterogeneity was only moderate (I2: 37{\%}). No publication bias was present. Conclusions Patients with low-risk adenomas at baseline had a higher risk of metachronous advanced neoplasia than the group with no adenomas at baseline, though the absolute risk was low in both groups.",
author = "C. Hassan and A. Gimeno-Garc{\'i}a and M. Kalager and C. Spada and A. Zullo and G. Costamagna and C. Senore and Rex, {D. K.} and E. Quintero",
year = "2014",
month = "5",
doi = "10.1111/apt.12682",
language = "English (US)",
volume = "39",
pages = "905--912",
journal = "Alimentary Pharmacology and Therapeutics",
issn = "0269-2813",
publisher = "Wiley-Blackwell",
number = "9",

}

TY - JOUR

T1 - Systematic review with meta-analysis

T2 - The incidence of advanced neoplasia after polypectomy in patients with and without low-risk adenomas

AU - Hassan, C.

AU - Gimeno-García, A.

AU - Kalager, M.

AU - Spada, C.

AU - Zullo, A.

AU - Costamagna, G.

AU - Senore, C.

AU - Rex, D. K.

AU - Quintero, E.

PY - 2014/5

Y1 - 2014/5

N2 - Background Patients with one to two tubular adenomas <1 cm in size without high-grade dysplasia (low-risk group) are considered at low risk for colorectal cancer. However, it is uncertain whether they have the same risk of subsequent advanced neoplasia as those with no neoplasia at baseline colonoscopy. Aim To compare incidence of metachronous advanced neoplasia between patients in the low-risk adenoma group and those without neoplasia at index colonoscopy. Methods Relevant publications were identified by MEDLINE/EMBASE and other databases for the period 1992-2013. Studies comparing the incidence of post-polypectomy advanced neoplasia (adenomas ≥10 mm/high-grade dysplasia/villous or cancer) between the low-risk group and patients without colorectal neoplasia at the first colonoscopy were included. Detection rates for advanced neoplasia at endoscopic surveillance were extracted. Study quality was ascertained according to Newcastle-Ottawa Scale. Forest plot was produced based on random-effect models. Inter-study heterogeneity was assessed using the I2 statistic. Results Seven studies provided data on 11 387 patients. Mean surveillance periods ranged between 2 and 5 years. Altogether, 267 patients with post-polypectomy advanced neoplasia were detected in the two groups. The incidence of advanced neoplasia was 1.6% (119/7308) in those without neoplasia and 3.6% (148/4079) in those with low-risk adenoma, respectively, corresponding to a relative risk of 1.8 (95% CI: 1.3-2.6). Inter-study heterogeneity was only moderate (I2: 37%). No publication bias was present. Conclusions Patients with low-risk adenomas at baseline had a higher risk of metachronous advanced neoplasia than the group with no adenomas at baseline, though the absolute risk was low in both groups.

AB - Background Patients with one to two tubular adenomas <1 cm in size without high-grade dysplasia (low-risk group) are considered at low risk for colorectal cancer. However, it is uncertain whether they have the same risk of subsequent advanced neoplasia as those with no neoplasia at baseline colonoscopy. Aim To compare incidence of metachronous advanced neoplasia between patients in the low-risk adenoma group and those without neoplasia at index colonoscopy. Methods Relevant publications were identified by MEDLINE/EMBASE and other databases for the period 1992-2013. Studies comparing the incidence of post-polypectomy advanced neoplasia (adenomas ≥10 mm/high-grade dysplasia/villous or cancer) between the low-risk group and patients without colorectal neoplasia at the first colonoscopy were included. Detection rates for advanced neoplasia at endoscopic surveillance were extracted. Study quality was ascertained according to Newcastle-Ottawa Scale. Forest plot was produced based on random-effect models. Inter-study heterogeneity was assessed using the I2 statistic. Results Seven studies provided data on 11 387 patients. Mean surveillance periods ranged between 2 and 5 years. Altogether, 267 patients with post-polypectomy advanced neoplasia were detected in the two groups. The incidence of advanced neoplasia was 1.6% (119/7308) in those without neoplasia and 3.6% (148/4079) in those with low-risk adenoma, respectively, corresponding to a relative risk of 1.8 (95% CI: 1.3-2.6). Inter-study heterogeneity was only moderate (I2: 37%). No publication bias was present. Conclusions Patients with low-risk adenomas at baseline had a higher risk of metachronous advanced neoplasia than the group with no adenomas at baseline, though the absolute risk was low in both groups.

UR - http://www.scopus.com/inward/record.url?scp=84898598352&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84898598352&partnerID=8YFLogxK

U2 - 10.1111/apt.12682

DO - 10.1111/apt.12682

M3 - Review article

C2 - 24593121

AN - SCOPUS:84898598352

VL - 39

SP - 905

EP - 912

JO - Alimentary Pharmacology and Therapeutics

JF - Alimentary Pharmacology and Therapeutics

SN - 0269-2813

IS - 9

ER -